03:38 , Jan 11, 2019 |  BC Innovations  |  Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...
22:48 , May 25, 2018 |  BC Extra  |  Company News

Management tracks: ISA, ImCheck, ArQule

Immunotherapy company ISA Pharmaceuticals B.V. (Leiden, the Netherlands) promoted CBO Gerben Moolhuizen to CEO, effective June 1. He succeeds CEO Ronald Loggers. Also in May, ISA hired Leon Hooftman as CMO. Hooftman was CMO at...
07:00 , Sep 22, 2016 |  BC Extra  |  Clinical News

Teva's SD-809 passes latest tardive dyskinesia test

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said two doses of SD-809 deutetrabenazine met the primary endpoint in the Phase III AIM-TD study to treat moderate to severe tardive dyskinesia. The company intends to submit an NDA...
01:19 , Jun 1, 2016 |  BC Extra  |  Company News

Teva gets CRL for Huntington's candidate

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) received an FDA complete response letter for SD-809 deutetrabenazine to treat chorea associated with Huntington's disease (HD). The company plans to submit its response to FDA next quarter. Teva gained...
01:29 , Oct 9, 2015 |  BC Extra  |  Clinical News

Neurocrine gains on Phase III dyskinesia data

Neurocrine Biosciences Inc. (NASDAQ:NBIX) gained $4.67 (12%) to $43.60 after its NBI-98854 met the primary endpoint in the Phase III Kinect 3 trial to treat tardive dyskinesia. Daily 80 mg doses of NBI-98854 significantly reduced...
07:00 , Sep 28, 2015 |  BioCentury  |  Regulation

Serving nerves

Testimony at the first of FDA's patient-focused drug development meetings last week revealed that several programs in industry's pipeline for Huntington's disease are aligned with patient and caregiver desires for drugs that could halt progression...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Auspex, Concert Pharmaceuticals deal

Auspex Pharmaceuticals Inc. , La Jolla, Calif.   Concert Pharmaceuticals Inc. (NASDAQ:CNCE), Lexington, Mass.   Business: Pharmaceuticals   Concert received a $50.2 million payment from Auspex under a September 2011 deal, which transferred IP related...
01:01 , Jun 17, 2015 |  BC Extra  |  Clinical News

Teva's Austedo meets in Phase III tardive dyskinesia study

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said Austedo deutetrabenazine ( SD-809 ) met the primary endpoint in the Phase III ARM-TD trial to treat moderate to severe tardive dyskinesia. Austedo led to an improvement of 3...
07:00 , May 11, 2015 |  BC Week In Review  |  Company News

Auspex, Teva deal

Teva completed its acquisition of neurology play Auspex for $101 per share in cash, or $3.5 billion (see BioCentury, April 6). Auspex Pharmaceuticals Inc. , La Jolla, Calif.   Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Company News

Auspex Pharmaceuticals Inc, Teva deal

Teva will acquire neurology play Auspex for $101 per share in cash, or about $3.5 billion. The price is a 42% premium to Auspex’s close of $70.91 on March 27, the last trading day before...